A Phase II Study to Evaluate the Safety and Efficacy of SAL003 Combined With Atorvastatin in Hypercholesterolemia and Mixed Dyslipidemia

NCT ID: NCT07278830

Last Updated: 2025-12-12

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 214 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-06-02
• Study Completion Date: 2024-06-07

Brief Summary

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy and safety of SAL003, a recombinant fully human anti-PCSK9 monoclonal antibody, in combination with a stable dose of atorvastatin in patients with hypercholesterolemia and mixed dyslipidemia.

Detailed Description

This is a Phase II, multicenter, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and pharmacokinetics of SAL003, a recombinant fully human anti-PCSK9 monoclonal antibody, when used in combination with stable, background atorvastatin therapy in adult patients with hypercholesterolemia and mixed dyslipidemia.

The study is structured into four distinct periods to ensure patient eligibility, standardize background therapy, and assess both short-term and longer-term effects of the investigational product.

Conditions

Hypercholesterolemia and Mixed Dyslipidemia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Test Group Q4W

Group Type: EXPERIMENTAL

SAL003 140mg+Atorvastatin

Intervention Type: DRUG

Double-blind treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 6 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Test Group Q8W

Group Type: EXPERIMENTAL

SAL003 420mg+Atorvastatin

Intervention Type: DRUG

Double-blind treatment period: During the stable dose of atorvastatin treatment, 420mg of SAL003 was administered once every 8 weeks for a total of 3 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Reference Group Q4W

Group Type: PLACEBO_COMPARATOR

Placebo 140mg+Atorvastatin

Intervention Type: DRUG

Double-blind treatment period: During the stable dose of atorvastatin treatment, 140mg of Placebo was administered once every 4 weeks for a total of 6 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Reference Group Q8W

Group Type: PLACEBO_COMPARATOR

Placebo 420mg+Atorvastatin

Intervention Type: DRUG

Double-blind treatment period: During the stable dose of atorvastatin treatment, 420mg of Placebo was administered once every 8 weeks for a total of 3 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Interventions

SAL003 140mg+Atorvastatin

Double-blind treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 6 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Intervention Type: DRUG

SAL003 420mg+Atorvastatin

Double-blind treatment period: During the stable dose of atorvastatin treatment, 420mg of SAL003 was administered once every 8 weeks for a total of 3 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Intervention Type: DRUG

Placebo 140mg+Atorvastatin

Double-blind treatment period: During the stable dose of atorvastatin treatment, 140mg of Placebo was administered once every 4 weeks for a total of 6 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Intervention Type: DRUG

Placebo 420mg+Atorvastatin

Double-blind treatment period: During the stable dose of atorvastatin treatment, 420mg of Placebo was administered once every 8 weeks for a total of 3 times. Extended treatment period: During the stable dose of atorvastatin treatment, 140mg of SAL003 was administered once every 4 weeks for a total of 2 times.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Subjects aged 18 to 75 years.

2. Diagnosis of hypercholesterolemia and/or mixed dyslipidemia per the 2016 Chinese guidelines.

3. On a stable statin regimen as defined by the two pathways:

• Pathway 1: On other statins or irregular atorvastatin, willing to switch to/stabilize on atorvastatin.
• Pathway 2: On stable, regular atorvastatin (Lipitor) for ≥4 weeks.

4. Fasting LDL-C must be above target:

• With ASCVD history: ≥1.8 mmol/L (70 mg/dL)
• Without ASCVD history: ≥2.6 mmol/L (100 mg/dL)

5. Fasting triglycerides (TG) ≤ 5.6 mmol/L (500 mg/dL) at screening.

6. Provide signed informed consent.

Exclusion Criteria

1. Suffering from homozygous familial hypercholesterolemia (HoFH); Other diseases that may cause secondary increase of LDL-C: Cushing's syndrome, nephrotic syndrome, myeloma, glycogen storage disease, systemic lupus erythematosus, acute intermittent porphyria;

2. Route 1: The medication compliance of atorvastatin during the induction period is less than 80% or more than 120%; Route 2: The medication compliance of atorvastatin within 28 days before screening is less than 80% or more than 120%;

3. Within 3 months before screening, there is heart failure (NYHA cardiac function classification of grade III and IV), acute coronary syndrome, percutaneous coronary intervention, or other serious heart diseases [such as cardiogenic shock, grade II-III atrioventricular block, bradycardia (heart rate < 50 beats/minute), other serious arrhythmias, etc.];

4. Within 3 months before screening, there is a serious cerebrovascular disease (hypertensive encephalopathy, cerebral vascular injury, stroke, transient ischemic attack, etc.), or there is a serious aortic or peripheral vascular lesion, or there are indications for surgical intervention;

5. Within 3 months before screening, there is a major surgical history or plans to undergo major surgery during the study period;

6. Patients with poorly controlled hypertension (SBP ≥ 160 mm Hg or DBP ≥ 100 mm Hg);

7. Diabetic patients with the following conditions known: 1) Type 1 diabetic patients; 2) Type 2 diabetic patients with poor blood sugar control (HbA1c > 8.0%);

8. Patients with active viral hepatitis (including hepatitis B and hepatitis C), other severe liver diseases, or liver dysfunction (ALT or AST > 2.5 times the upper limit of normal, TBIL > 2 times the upper limit of normal);

9. Glomerular filtration rate (eGFR) < 30 ml/min/1.73m2 during the screening period;

10. Patients with abnormal thyroid function (thyroid stimulating hormone TSH exceeds the normal range of the center);

11. CK > 3 times the upper limit of normal during the screening period;

12. Positive for AIDS or syphilis tests;

13. Active malignant tumors, or patients with a history of malignant tumors within 5 years before screening (excluding skin basal cell carcinoma or cervical carcinoma in situ);

14. Patients known to be allergic to the test drug or any component of the test drug, or who have had a severe allergic reaction to other antibody-based drugs;

15. Patients with a history of organ transplantation;

16. Within 3 months before screening, blood donation or significant blood loss (> 400 mL), or those diagnosed with insufficient blood volume;

17. Within 30 days before the administration of the study drug, use of any known substances that can affect lipid metabolism, tonics (such as fish oil > 1000 mg/day, drugs containing red yeast rice components or health supplements), or other cholesterol-lowering drugs other than statins;

18. Within 3 months before screening, participated in other drug or device clinical trials, or within 6 months before screening received any treatment targeting the proprotein convertase subtilisin/kexin type 9 (PCSK9) target;

19. Within 6 months before screening had a history of drug abuse or alcoholism (14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);

20. Female subjects during the screening period or during the trial are breastfeeding or have a positive serum pregnancy result;

21. The subject or the subject's spouse or partner has a pregnancy plan or refuses to adopt an acceptable effective contraceptive method from the time of signing the informed consent form to the end of the last administration;

22. The subject and his/her spouse or partner have a pregnancy plan or refuse to adopt an acceptable effective contraceptive method from the time of signing the informed consent form to the end of the last administration within 6 months;

23. Patients considered not suitable for participating in the clinical trial by the investigator.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 75 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Salubris (Chengdu) Biotechnology Co., Ltd.

UNKNOWN

Sponsor Role: collaborator

Shenzhen Salubris Pharmaceuticals Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Sun Yat-sen Memorial Hospital, Sun Yat-sen University，Guangzhou，Guangdong，510120

Guangzhou, Guangdong, China

Countries

China

Other Identifiers

SAL003A201

Identifier Type: -

Identifier Source: org_study_id